1-20 of 52
gilteritinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei
Journal: Blood
Blood (2020) 135 (2): 85–96.
https://doi.org/10.1182/blood.2019001239
Published: 2020
Includes: Supplemental data
Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2213.
https://doi.org/10.1182/blood-2019-127075
Published: 2019
Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai
Journal: Blood
Blood (2019) 134 (Supplement_1): 2551.
https://doi.org/10.1182/blood-2019-131101
Published: 2019
Journal Articles

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Yuichi Ishikawa, MD PhD, Koichi Saito, PhD, Naomi Kawashima, MD PhD, Michie Morimoto, Hidetoshi Murao, PhD, Daisuke Terada, Takeshi Yamaura, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2672.
https://doi.org/10.1182/blood-2019-124632
Published: 2019
Journal Articles

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

Ruiqi Zhu, PhD, Li Li, MD PhD, Bao Nguyen, MS, Amy S. Duffield, MD PhD, Donald Small, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2564.
https://doi.org/10.1182/blood-2019-131635
Published: 2019
Journal Articles

Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations

Mary Figueroa, BS, Mansour Alfayez, MD, Yue Lu, PhD, Marcos Estecio, PhD, Seyed Javad Moghaddam, MD, Marina Y Konopleva, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MDMSc, Joya Chandra, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2554.
https://doi.org/10.1182/blood-2019-127216
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3859.
https://doi.org/10.1182/blood-2019-123819
Published: 2019
Journal Articles

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

Alexander E. Perl, MD, Naval G. Daver, MD, Keith W. Pratz, MD, Joseph Maly, MD, Wan-Jen Hong, MD, Erkut Bahceci, Bo Tong, PhD, Tian Tian, PhD, Kimberley Dilley, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3910.
https://doi.org/10.1182/blood-2019-127416
Published: 2019
Journal Articles

The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3 -Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study

David Cella, PhD, Ellen K. Ritchie, MD, Francesco Fabbiano, Arnaud Pigneux, Yoshinobu Kanda, MD PhD, Cristina Ivanescu, PhD, Bhavik J. Pandya, PharmD, Manasee V Shah, MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3850.
https://doi.org/10.1182/blood-2019-123790
Published: 2019
Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 64.
https://doi.org/10.1182/blood-2019-128905
Published: 2019
Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2865.
https://doi.org/10.1182/blood-2019-130633
Published: 2019
Journal Articles

The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML

Tristan Knight, MD, Xinan Qiao, BS, Jun Ma, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Kathryn White, Hai Lin, MD, Yue Wang, Jeffrey W. Taub, MD, Yubin Ge, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1262.
https://doi.org/10.1182/blood-2019-123793
Published: 2019
Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1264.
https://doi.org/10.1182/blood-2019-124685
Published: 2019
Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1267.
https://doi.org/10.1182/blood-2019-125725
Published: 2019
Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1276.
https://doi.org/10.1182/blood-2019-129011
Published: 2019
Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood
Blood (2019) 134 (Supplement_1): 14.
https://doi.org/10.1182/blood-2019-122620
Published: 2019
Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 910.
https://doi.org/10.1182/blood-2019-130694
Published: 2019
Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1373.
https://doi.org/10.1182/blood-2019-124030
Published: 2019
Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5082.
https://doi.org/10.1182/blood-2019-123535
Published: 2019
Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5141.
https://doi.org/10.1182/blood-2019-123589
Published: 2019